[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Dolasetron.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dolasetron.]
[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Dolasetron.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Dolasetron.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Dolasetron.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Dolasetron is combined with Sulthiame.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Dolasetron.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Dolasetron.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Dolasetron.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Tetracaine.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Dolasetron is combined with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Dolasetron.]
[N04BC07, apomorphine, The risk or severity of hypotension can be increased when Dolasetron is combined with Apomorphine.]
[L04AX02, thalidomide, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Dolasetron.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Dolasetron.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Dolasetron.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Thiopental is combined with Dolasetron.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Dolasetron is combined with Thiothixene.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Dolasetron.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Dolasetron is combined with Tiapride.]
[B01AC05, ticlopidine, The metabolism of Dolasetron can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Tilidine.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Dolasetron.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Dolasetron is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Dolasetron is combined with Tramadol.]
[N06AF04, tranylcypromine, The metabolism of Dolasetron can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Dolasetron.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Dolasetron is combined with Triazolam.]
[A03AB12, mepenzolate, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Trifluoperazine.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Dolasetron is combined with Trifluperidol.]
[N05AA05, triflupromazine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Dolasetron.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Dolasetron.]
[R06AC04, tripelennamine, The metabolism of Dolasetron can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Dolasetron.]
[A03BB01, butylscopolamine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Dolasetron can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Dolasetron can be decreased when combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Dolasetron.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Tubocurarine.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Vandetanib.]
[L02BX03, abiraterone, The metabolism of Dolasetron can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The metabolism of Dolasetron can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Dolasetron can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Dolasetron can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Dolasetron can be decreased when combined with Rilpivirine.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Ezogabine.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Dolasetron.]
[C08DA01, verapamil, The metabolism of Dolasetron can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Dolasetron can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Dolasetron can be decreased when combined with Vinblastine.]
[B01AA03, warfarin, The risk or severity of adverse effects can be increased when Dolasetron is combined with Warfarin.]
[S01AA13, fusidic acid, The metabolism of Dolasetron can be decreased when combined with Fusidic acid.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Dolasetron can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Dolasetron is combined with Levetiracetam.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Vemurafenib.]
[L01ED01, crizotinib, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Crizotinib.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dolasetron.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Ziprasidone.]
[G04BD07, tolterodine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[C07AB03, atenolol, The metabolism of Dolasetron can be decreased when combined with Atenolol.]
[J02AC03, voriconazole, The metabolism of Dolasetron can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Dolasetron is combined with Atracurium.]
[S01FA01, atropine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Dolasetron.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Dolasetron.]
[A08AA11, lorcaserin, The metabolism of Dolasetron can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Dolasetron can be increased when it is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Dolasetron can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Dolasetron can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Dolasetron can be decreased when it is combined with Enzalutamide.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Dolasetron is combined with Barbital.]
[J05AE04, nelfinavir, The metabolism of Dolasetron can be decreased when combined with Nelfinavir.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Dolasetron.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Dolasetron is combined with Rasagiline.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Dolasetron is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Dolasetron is combined with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Dolasetron.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Dolasetron.]
[R06AC06, thonzylamine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, The metabolism of Dolasetron can be decreased when combined with Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Dolasetron is combined with Diethyl ether.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Dolasetron.]
[G04BE03, sildenafil, The metabolism of Dolasetron can be decreased when combined with Sildenafil.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Dolasetron.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Dolasetron.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be decreased when combined with Dolasetron.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Dolasetron can be decreased when combined with Glycerol phenylbutyrate.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Dolasetron is combined with Pomalidomide.]
[G03XC05, ospemifene, The metabolism of Dolasetron can be decreased when combined with Ospemifene.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Dolasetron is combined with Benperidol.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Dolasetron.]
[A06AX06, tegaserod, The metabolism of Dolasetron can be decreased when combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Benzocaine.]
[M01AH01, celecoxib, The metabolism of Dolasetron can be decreased when combined with Celecoxib.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Dolasetron is combined with Naratriptan.]
[L04AA18, everolimus, The metabolism of Dolasetron can be decreased when combined with Everolimus.]
[N04AC01, benztropine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Dolasetron can be decreased when it is combined with Dabrafenib.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Dolasetron is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Dolasetron is combined with Levomilnacipran.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Bepridil.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Dolasetron.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Vortioxetine.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Dolasetron can be decreased when combined with Simeprevir.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Dolasetron is combined with Vigabatrin.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Dolasetron.]
[C07AB04, acebutolol, The metabolism of Dolasetron can be decreased when combined with Acebutolol.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Dolasetron is combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Dolasetron can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Dolasetron can be increased when combined with Apremilast.]
[S01ED02, betaxolol, The metabolism of Dolasetron can be decreased when combined with Betaxolol.]
[L04AC11, siltuximab, The metabolism of Dolasetron can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Ceritinib.]
[A03BA03, hyoscyamine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The risk or severity of adverse effects can be increased when Dolasetron is combined with Acenocoumarol.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Dolasetron is combined with Alfaxalone.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Dolasetron.]
[D11AA01, glycopyrronium, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The metabolism of Dolasetron can be decreased when combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Dolasetron can be decreased when combined with Oritavancin.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Acepromazine.]
[N04AA02, biperiden, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Dolasetron.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Dolasetron.]
[B01AA01, dicumarol, The risk or severity of adverse effects can be increased when Dolasetron is combined with Dicoumarol.]
[N06AX11, mirtazapine, Dolasetron may increase the serotonergic activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Dolasetron can be increased when combined with Secukinumab.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Lenvatinib.]
[L01XH03, panobinostat, The metabolism of Dolasetron can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, The metabolism of Dolasetron can be decreased when combined with Acetaminophen.]
[A03AA09, difemerine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of adverse effects can be increased when Dolasetron is combined with Tioclomarol.]
[C01EB17, ivabradine, Ivabradine may increase the QTc-prolonging activities of Dolasetron.]
[J05AP06, asunaprevir, The metabolism of Dolasetron can be decreased when combined with Asunaprevir.]
[A07DA06, eluxadoline, The risk or severity of serotonin syndrome can be increased when Dolasetron is combined with Eluxadoline.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Dolasetron is combined with Brexpiprazole.]
[A04AD14, rolapitant, The metabolism of Dolasetron can be decreased when combined with Rolapitant.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Dolasetron is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Cariprazine.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Dolasetron is combined with Acetazolamide.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Acetophenazine.]
[A02BC03, lansoprazole, The metabolism of Dolasetron can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Dolasetron.]
[J02AC05, isavuconazole, The metabolism of Dolasetron can be decreased when combined with Isavuconazole.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Dolasetron.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Dolasetron is combined with Aprobarbital.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Dolasetron is combined with Brivaracetam.]
[L01XX52, venetoclax, The metabolism of Dolasetron can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Dolasetron is combined with Bromazepam.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Bromocriptine.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dolasetron.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Dolasetron is combined with Amineptine.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Dolasetron is combined with Aniracetam.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dolasetron.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Dolasetron.]
[N07BC01, buprenorphine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Dolasetron.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Dolasetron.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Artemether.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Dolasetron.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Dolasetron.]
[S01GX07, azelastine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Dolasetron can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Dolasetron.]
[L01EF02, ribociclib, The metabolism of Dolasetron can be decreased when combined with Ribociclib.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The therapeutic efficacy of Dolasetron can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Dolasetron is combined with Beclamide.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Dolasetron is combined with Oxybuprocaine.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Dolasetron.]
[J05AE09, tipranavir, The metabolism of Dolasetron can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Dolasetron.]
[L04AB02, infliximab, The metabolism of Dolasetron can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Dolasetron can be decreased when combined with Midostaurin.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Dolasetron is combined with Safinamide.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Dolasetron.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Dolasetron.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Dolasetron.]
[J05AG03, efavirenz, The metabolism of Dolasetron can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, The metabolism of Bopindolol can be decreased when combined with Dolasetron.]
[N04AA11, bornaprine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Dolasetron is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Dolasetron is combined with Brotizolam.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Dolasetron is combined with Butobarbital.]
[J05AX18, letermovir, The metabolism of Letermovir can be decreased when combined with Dolasetron.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Dolasetron.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Dolasetron is combined with Vinylbital.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Dolasetron.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Macimorelin.]
[L02BB05, apalutamide, The metabolism of Dolasetron can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Dolasetron can be increased when combined with Carbamazepine.]
[A03AA03, camylofine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Dolasetron.]
[C07AG02, carvedilol, The metabolism of Carvedilol can be decreased when combined with Dolasetron.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Dolasetron.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Encorafenib.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Dolasetron.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Dolasetron.]
[L01XX62, ivosidenib, The metabolism of Dolasetron can be increased when combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Dolasetron.]
[N03AX17, stiripentol, The metabolism of Dolasetron can be decreased when combined with Stiripentol.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Dolasetron.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Dolasetron.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Dolasetron is combined with Carbromal.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Chloroprocaine.]
[R06AA06, chlorphenoxamine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Dolasetron.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Dolasetron.]
[R03BB08, revefenacin, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L04AA39, emapalumab, The metabolism of Dolasetron can be increased when combined with Emapalumab.]
[L01EX13, gilteritinib, The therapeutic efficacy of Dolasetron can be decreased when used in combination with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Amifampridine.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Dolasetron.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Dolasetron.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Dolasetron is combined with Cinitapride.]
[P02BX04, triclabendazole, The metabolism of Dolasetron can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Esketamine.]
[J01FA09, clarithromycin, The metabolism of Dolasetron can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Dolasetron is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Dolasetron is combined with Brexanolone.]
[N05BA09, clobazam, The metabolism of Dolasetron can be decreased when combined with Clobazam.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Dolasetron is combined with Cloxazolam.]
[L04AB01, etanercept, The metabolism of Dolasetron can be increased when combined with Etanercept.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Cyamemazine.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Dolasetron.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Dolasetron.]
[L01EJ02, fedratinib, The metabolism of Dolasetron can be decreased when combined with Fedratinib.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Dolasetron can be decreased when it is combined with Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Dolasetron.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Dolasetron.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Yohimbine.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Dolasetron.]
[N03AX25, cenobamate, The serum concentration of Dolasetron can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Dolasetron can be increased when it is combined with Givosiran.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dolasetron.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Dexchlorpheniramine.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Dezocine.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Dolasetron is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Dolasetron is combined with Lumateperone.]
[M01AX21, diacetylrhein, The metabolism of Dolasetron can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Dolasetron.]
[H02CA02, osilodrostat, The metabolism of Dolasetron can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Dolasetron can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Dolasetron is combined with Frovatriptan.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Dolasetron is combined with Dichloralphenazone.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Dolasetron is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Dolasetron.]
[C08CA16, clevidipine, The metabolism of Clevidipine can be decreased when combined with Dolasetron.]
[C01BD07, dronedarone, The metabolism of Dolasetron can be decreased when combined with Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Dolasetron is combined with Valpromide.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Dolasetron.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dolasetron.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Dolasetron.]
[A03AA08, dihexyverine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[G04BD09, trospium, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Dolasetron is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Dolasetron is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Dolasetron.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Dolasetron.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Dolasetron.]
[P01BB01, proguanil, The metabolism of Dolasetron can be decreased when combined with Proguanil.]
[N05CD14, remimazolam, The risk or severity of sedation can be increased when Dolasetron is combined with Remimazolam.]
[L04AC19, satralizumab, The serum concentration of Dolasetron can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Dolasetron is combined with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Dolasetron can be decreased when combined with Chloroquine.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Dolasetron can be decreased when combined with Chlorpromazine.]
[N05AF03, chlorprothixene, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dolasetron.]
[A11CC05, cholecalciferol, The metabolism of Dolasetron can be decreased when combined with Cholecalciferol.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Etifoxine.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Dolasetron is combined with Ethyl loflazepate.]
[B06AC06, berotralstat, The metabolism of Dolasetron can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Dolasetron can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Dolasetron.]
[P03AX07, abametapir, The serum concentration of Dolasetron can be increased when it is combined with Abametapir.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Dolasetron is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Dolasetron is combined with Felbamate.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Dolasetron.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Dolasetron.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Dolasetron.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Dolasetron is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The metabolism of Dolasetron can be decreased when combined with Peginterferon alfa-2b.]
[A02BA01, cimetidine, The metabolism of Dolasetron can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Dolasetron is combined with Gabapentin.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Dolasetron.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Dolasetron can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Dolasetron.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Citalopram.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Dolasetron is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Clemastine.]
[N06AX25, St. John's wort extract, The metabolism of Dolasetron can be increased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Dolasetron.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Dolasetron.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Dolasetron.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Dolasetron.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Dolasetron is combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Dolasetron.]
[C01EB24, mavacamten, The serum concentration of Dolasetron can be decreased when it is combined with Mavacamten.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Dolasetron is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Granisetron.]
[N05AH02, clozapine, The metabolism of Dolasetron can be decreased when combined with Clozapine.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Dolasetron is combined with Halazepam.]
[H01AC08, somatrogon, The metabolism of Dolasetron can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Cocaine.]
[C02KB01, metyrosine, Dolasetron may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Dolasetron can be increased when combined with Bimekizumab.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Dolasetron.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Dolasetron is combined with Hexafluronium.]
[A03AB10, hexocyclium, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Dolasetron is combined with Desflurane.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Dolasetron is combined with Ifenprodil.]
[A10BX03, nateglinide, The metabolism of Dolasetron can be decreased when combined with Nateglinide.]
[J01FA15, telithromycin, The metabolism of Dolasetron can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be decreased when combined with Dolasetron.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Desloratadine.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Dolasetron is combined with Almotriptan.]
[J02AC02, itraconazole, The metabolism of Dolasetron can be decreased when combined with Itraconazole.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Emedastine.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Dolasetron is combined with Ketazolam.]
[L01EA01, imatinib, The serum concentration of Dolasetron can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Dolasetron can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Dolasetron.]
[N03AX09, lamotrigine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Dolasetron.]
[N07BC04, lofexidine, The therapeutic efficacy of Dolasetron can be increased when used in combination with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Lomefloxacin.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Dolasetron is combined with Lormetazepam.]
[C08CA11, manidipine, The metabolism of Dolasetron can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Medifoxamine.]
[C07AA14, mepindolol, The metabolism of Mepindolol can be decreased when combined with Dolasetron.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Dolasetron.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Dolasetron.]
[N04AA03, methixene, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R03CB02, methoxyphenamine, The risk or severity of serotonin syndrome can be increased when Dolasetron is combined with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Dolasetron is combined with Cyclobarbital.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Melperone.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Minaprine.]
[S01XA18, cyclosporine, The metabolism of Dolasetron can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Dolasetron is combined with Moclobemide.]
[R06AX02, cyproheptadine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Dolasetron.]
[C03XA02, conivaptan, The metabolism of Dolasetron can be decreased when combined with Conivaptan.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Dolasetron.]
[M01AH05, etoricoxib, The metabolism of Dolasetron can be decreased when combined with Etoricoxib.]
[G03XA01, danazol, The metabolism of Dolasetron can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Dolasetron is combined with Dantrolene.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Dolasetron is combined with Deanol.]
[C02CC04, debrisoquin, The metabolism of Debrisoquine can be decreased when combined with Dolasetron.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Dolasetron.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Dolasetron is combined with Nordazepam.]
[C07AB12, nebivolol, The metabolism of Nebivolol can be decreased when combined with Dolasetron.]
[N06AX06, nefazodone, The metabolism of Dolasetron can be decreased when combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Niaprazine.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Tiagabine.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Dolasetron.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Dolasetron is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Dolasetron is combined with Escitalopram.]
[G04BD08, solifenacin, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[N06AA01, desipramine, The metabolism of Dolasetron can be decreased when combined with Desipramine.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Dolasetron.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Dolasetron can be increased when combined with Dexamethasone.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Dolasetron is combined with Oxiracetam.]
[N04AA08, dexetimide, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The risk or severity of serotonin syndrome can be increased when Dolasetron is combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Dolasetron can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Dolasetron can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Dolasetron.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Dolasetron.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Dolasetron.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Dolasetron is combined with Dextromoramide.]
[N06AB05, paroxetine, The metabolism of Dolasetron can be decreased when combined with Paroxetine.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Dolasetron is combined with Diamorphine.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Dolasetron is combined with Diazepam.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Dolasetron is combined with Phenacemide.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Dolasetron is combined with Phensuximide.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Dolasetron is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Dolasetron.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Dolasetron.]
[A03AA07, dicyclomine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Dolasetron.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Dolasetron is combined with Pipamperone.]
[A03AB14, pipenzolate, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Dolasetron.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Dolasetron is combined with Diethylpropion.]
[C08CA03, isradipine, The metabolism of Dolasetron can be decreased when combined with Isradipine.]
[A03AB11, poldine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Dolasetron.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Dolasetron.]
[N02CA01, dihydroergotamine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Dolasetron.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dolasetron.]
[J05AE08, atazanavir, The metabolism of Dolasetron can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Dolasetron.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Pramocaine.]
[C08DB01, diltiazem, The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Dolasetron.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Dimenhydrinate.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Dolasetron is combined with Pridinol.]
[R06AB03, dimethindene, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[M02AX03, dimethyl sulfoxide, The metabolism of Dolasetron can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Dolasetron is combined with Progabide.]
[R06AA02, diphenhydramine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Dolasetron is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Dolasetron is combined with Quazepam.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Dolasetron is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Cisapride.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Dolasetron.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Disopyramide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Dolasetron.]
[S02AA12, rifamycin SV, The metabolism of Dolasetron can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Dolasetron can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Dolasetron.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Risperidone is combined with Dolasetron.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dolasetron.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Dolasetron.]
[L01EX01, sunitinib, The risk or severity of QTc prolongation and torsade de pointes can be increased when Sunitinib is combined with Dolasetron.]
[A04AD12, aprepitant, The metabolism of Dolasetron can be decreased when combined with Aprepitant.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Dolasetron.]
[C01EB18, ranolazine, The serum concentration of Dolasetron can be increased when it is combined with Ranolazine.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Dolasetron.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Domperidone.]
[N06AA16, dothiepin, The metabolism of Dolasetron can be decreased when combined with Dosulepin.]
[N06AA12, doxepin, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L01DB01, doxorubicin, The metabolism of Dolasetron can be decreased when combined with Doxorubicin.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dolasetron.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Dolasetron is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Dolasetron is combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Dolasetron.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Sibutramine.]
[C10AA01, simvastatin, The metabolism of Dolasetron can be decreased when combined with Simvastatin.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Dolasetron.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Talinolol is combined with Dolasetron.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Temafloxacin.]
[D01BA02, terbinafine, The metabolism of Dolasetron can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Terodiline.]
[C07AA16, tertatolol, The metabolism of Tertatolol can be decreased when combined with Dolasetron.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Dolasetron is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Dolasetron is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Dolasetron is combined with Thiopropazate.]
[G04BD01, emepronium, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Tianeptine.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Dolasetron is combined with Tofisopam.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Dolasetron is combined with Toloxatone.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Dolasetron.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Dolasetron.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Toremifene.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Dolasetron is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Dolasetron is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Dolasetron is combined with Triclofos.]
[A03AB08, tridihexethyl, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Dolasetron.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Dolasetron.]
[N04AA12, tropatepine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Dolasetron.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Dolasetron is combined with Urapidil.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Dolasetron.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Dolasetron is combined with Veralipride.]
[L01CA04, vinorelbine, The metabolism of Dolasetron can be decreased when combined with Vinorelbine.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Dolasetron.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Dolasetron is combined with Venlafaxine.]
[C08CA12, mepirodipine, The metabolism of Dolasetron can be decreased when combined with Barnidipine.]
[N05CF02, zolpidem, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Dolasetron is combined with Zonisamide.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Dolasetron is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Zotepine.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Guanfacine.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Moricizine is combined with Dolasetron.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Dolasetron is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The metabolism of Dolasetron can be decreased when combined with Ergotamine.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Valproic acid.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Dolasetron.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Dolasetron is combined with Estazolam.]
[H05BX01, cinacalcet, The metabolism of Dolasetron can be decreased when combined with Cinacalcet.]
[J04AK02, ethambutol, The metabolism of Dolasetron can be decreased when combined with Ethambutol.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Dolasetron.]
[C01CA15, gepefrine, The risk or severity of serotonin syndrome can be increased when Dolasetron is combined with Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dolasetron.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Ibutilide.]
[N04AA05, profenamine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Dolasetron.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Dolasetron.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Ethylmorphine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Dolasetron.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Dolasetron is combined with Sertindole.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Dolasetron.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Dolasetron.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Dolasetron.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Dolasetron.]
[R06AX12, terfenadine, The metabolism of Dolasetron can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The metabolism of Dolasetron can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Dolasetron can be decreased when combined with Fluvoxamine.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Dolasetron.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Dolasetron.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Dolasetron.]
[C08CA02, felodipine, The metabolism of Dolasetron can be decreased when combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Fendiline.]
[N03AX26, fenfluramine, The risk or severity of serotonin syndrome can be increased when Dolasetron is combined with Fenfluramine.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Dolasetron is combined with Fentanyl.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Dolasetron.]
[N07AX03, cevimeline, The metabolism of Dolasetron can be decreased when combined with Cevimeline.]
[G04BD02, flavoxate, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Dolasetron.]
[J02AC01, fluconazole, The metabolism of Dolasetron can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Dolasetron is combined with Flunitrazepam.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Dolasetron is combined with Melitracen.]
[V03AZ01, ethanol, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Dolasetron.]
[N06AB03, fluoxetine, The serum concentration of Dolasetron can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Dolasetron.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Dolasetron.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Fluspirilene.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Dolasetron is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Furazolidone is combined with Dolasetron.]
[J05AE10, darunavir, The metabolism of Dolasetron can be decreased when combined with Darunavir.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Dolasetron is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Dolasetron.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Gallamine.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Dolasetron.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Dolasetron is combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Dolasetron is combined with Bifemelane.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Dolasetron.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Dolasetron.]
[N04BC06, cabergoline, The risk or severity of adverse effects can be increased when Cabergoline is combined with Dolasetron.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Dolasetron is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Dolasetron is combined with Alfentanil.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Dolasetron.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dolasetron.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Dolasetron is combined with Glutethimide.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Dofetilide.]
[C02CA04, doxazosin, The metabolism of Dolasetron can be decreased when combined with Doxazosin.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Dolasetron.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Dolasetron.]
[B01AA12, fluindione, The risk or severity of adverse effects can be increased when Dolasetron is combined with Fluindione.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Dolasetron.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Haloperidol.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Dolasetron is combined with Halothane.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Dolasetron.]
[N05AH04, quetiapine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Dolasetron is combined with Iprazochrome.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Dolasetron is combined with Allobarbital.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Dolasetron.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Dolasetron is combined with Hexobarbital.]
[J05AG01, nevirapine, The metabolism of Dolasetron can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Nilvadipine.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Oxatomide.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Dolasetron.]
[R05DA03, hydrocodone, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[G04BD06, propiverine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The metabolism of Dolasetron can be decreased when combined with Hydroxychloroquine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Dolasetron is combined with Prothipendyl.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Hydroxyzine.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Dolasetron.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Dolasetron.]
[N06AA02, imipramine, The metabolism of Dolasetron can be decreased when combined with Imipramine.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Terlipressin.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Dolasetron.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Dolasetron.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Dolasetron is combined with Milnacipran.]
[A03AA30, piperidolate, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Articaine.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Dolasetron.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Dolasetron is combined with Ramelteon.]
[R06AE01, buclizine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C10AA06, cerivastatin, The metabolism of Dolasetron can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Anagrelide.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Dolasetron is combined with Alprenolol.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Dolasetron.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Dolasetron is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Dolasetron is combined with Iproniazid.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Dolasetron is combined with Isocarboxazid.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Dolasetron.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Dolasetron.]
[J04AC01, isoniazid, The metabolism of Dolasetron can be decreased when combined with Isoniazid.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Dolasetron.]
[L04AC07, tocilizumab, The metabolism of Dolasetron can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Dolasetron is combined with Ketanserin.]
[J02AB02, ketoconazole, The metabolism of Dolasetron can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Dolasetron can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.]
[L04AA24, abatacept, The metabolism of Dolasetron can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Mizolastine.]
[N04BC09, rotigotine, Dolasetron may increase the sedative activities of Rotigotine.]
[C07AG01, labetalol, The metabolism of Dolasetron can be decreased when combined with Labetalol.]
[N04BB01, amantadine, The risk or severity of serotonin syndrome can be increased when Dolasetron is combined with Amantadine.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Dolasetron is combined with Lacosamide.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Dolasetron is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Dolasetron.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Dolasetron.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Lisuride is combined with Dolasetron.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Lofepramine.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Loperamide.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Dolasetron.]
[C10AA02, lovastatin, The metabolism of Dolasetron can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Dolasetron.]
[L01EG01, temsirolimus, The metabolism of Dolasetron can be decreased when combined with Temsirolimus.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Dolasetron can be increased when used in combination with Magnesium sulfate.]
[L01EA03, nilotinib, The metabolism of Dolasetron can be decreased when combined with Nilotinib.]
[N06AA21, maprotiline, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Dolasetron.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Dolasetron.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Dolasetron is combined with Medazepam.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Dolasetron.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Dolasetron is combined with Melatonin.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Meperidine is combined with Dolasetron.]
[C01CA11, mephentermine, The risk or severity of serotonin syndrome can be increased when Dolasetron is combined with Mephentermine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Dolasetron.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Dolasetron is combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Dolasetron.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Dolasetron is combined with Meptazinol.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Paliperidone.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Dolasetron.]
[N07XX04, sodium oxybate, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Nalidixic acid.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Dolasetron.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Metamfetamine.]
[A03AB07, methantheline, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Dolasetron is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Dolasetron is combined with Methaqualone.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Dolasetron.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Dolasetron is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Dolasetron can be decreased when combined with Methimazole.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Dolasetron.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methohexital is combined with Dolasetron.]
[N02BG08, ziconotide, The risk or severity of adverse effects can be increased when Dolasetron is combined with Ziconotide.]
[N05AA02, methotrimeprazine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Dolasetron is combined with Methoxyflurane.]
[V04CG05, methylene blue, Dolasetron may increase the serotonergic activities of Methylene blue.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Dolasetron.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Dolasetron is combined with Methyprylon.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Dolasetron.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Dolasetron.]
[C07AB02, metoprolol, The metabolism of Dolasetron can be decreased when combined with Metoprolol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Dolasetron.]
[C01BB02, mexiletine, The metabolism of Dolasetron can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Dolasetron is combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Dolasetron can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Dolasetron.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Dolasetron.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Mifepristone.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dolasetron.]
[L01XX23, mitotane, The metabolism of Dolasetron can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The risk or severity of serotonin syndrome can be increased when Dolasetron is combined with Lisdexamfetamine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Dolasetron is combined with Molindone.]
[C01BD01, amiodarone, The metabolism of Dolasetron can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Dolasetron.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Dolasetron.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Dolasetron.]
[L04AB05, certolizumab pegol, The metabolism of Dolasetron can be increased when combined with Certolizumab pegol.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Pazopanib.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Dolasetron is combined with Vecuronium.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Dolasetron is combined with Amobarbital.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Dolasetron.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be decreased when combined with Dolasetron.]
[N03AB05, fosphenytoin, The metabolism of Dolasetron can be increased when combined with Fosphenytoin.]
[C07AA12, nadolol, The metabolism of Nadolol can be decreased when combined with Dolasetron.]
[N04BC04, ropinirole, Dolasetron may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Dolasetron is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Nalbuphine.]
[V03AB15, naloxone, The metabolism of Dolasetron can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Dolasetron.]
[L04AC03, anakinra, The metabolism of Dolasetron can be increased when combined with Anakinra.]
[N06BA01, amphetamine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Dolasetron.]
[N06AX21, duloxetine, The metabolism of Dolasetron can be decreased when combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Dolasetron.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Dolasetron is combined with Remifentanil.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Levosimendan.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Iloperidone.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Desvenlafaxine.]
[C10AD02, niacin, The metabolism of Dolasetron can be decreased when combined with Niacin.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Dolasetron is combined with Nialamide.]
[C08CA04, nicardipine, The metabolism of Dolasetron can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, The metabolism of Dolasetron can be decreased when combined with Nicergoline.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Nifedipine.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Dolasetron.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Dolasetron is combined with Nitrazepam.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Dolasetron.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Dolasetron is combined with Zaleplon.]
[N04BC05, pramipexole, Dolasetron may increase the sedative activities of Pramipexole.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Dolasetron is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Nomifensine.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Dolasetron.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Dolasetron.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dolasetron.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Ofloxacin.]
[L04AC04, rilonacept, The metabolism of Dolasetron can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Dolasetron can be decreased when combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Dolasetron is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Dolasetron is combined with Opium.]
[G04CA02, tamsulosin, The metabolism of Dolasetron can be decreased when combined with Tamsulosin.]
[P02BA02, oxamniquine, The metabolism of Dolasetron can be decreased when combined with Oxamniquine.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Dolasetron is combined with Oxazepam.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Dolasetron.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Dolasetron is combined with Oxprenolol.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Oxycodone is combined with Dolasetron.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Dolasetron is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Oxypertine.]
[A03AB03, oxyphenonium, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dolasetron.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dolasetron.]
[M03AC01, pancuronium, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Papaverine.]
[N05CC05, paraldehyde, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Dolasetron is combined with Pargyline.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Dolasetron.]
[G04BD11, fesoterodine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Dolasetron is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Penfluridol.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Pentazocine is combined with Dolasetron.]
[N05CA01, pentobarbital, The metabolism of Dolasetron can be increased when combined with Pentobarbital.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Dolasetron is combined with Pergolide.]
[C08EX02, perhexiline, The metabolism of Dolasetron can be decreased when combined with Perhexiline.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Dolasetron.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Phenazocine.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Phenelzine.]
[A10BA01, phenformin, The metabolism of Phenformin can be decreased when combined with Dolasetron.]
[B01AA02, phenindione, The risk or severity of adverse effects can be increased when Dolasetron is combined with Phenindione.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Dolasetron.]
[N03AA02, phenobarbital, The metabolism of Dolasetron can be increased when combined with Phenobarbital.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Phenoperidine.]
[B01AA04, phenprocoumon, The risk or severity of adverse effects can be increased when Dolasetron is combined with Phenprocoumon.]
[A08AA01, phentermine, The risk or severity of serotonin syndrome can be increased when Phentermine is combined with Dolasetron.]
[N03AB02, phenytoin, The metabolism of Dolasetron can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Dolasetron can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Levofloxacin.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Dolasetron.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Dolasetron is combined with Pindolol.]
[J05AE01, saquinavir, The metabolism of Dolasetron can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Dolasetron can be decreased when combined with Piperazine.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Pipotiazine.]
[A02BX03, pirenzepine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Dolasetron is combined with Piritramide.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Grepafloxacin.]
[N02CX01, pizotyline, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Dolasetron can be decreased when combined with Delavirdine.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Dolasetron is combined with Proxibarbal.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Dolasetron can be increased when combined with Canakinumab.]
[J05AE03, ritonavir, The serum concentration of Dolasetron can be increased when it is combined with Ritonavir.]
[C07AB01, practolol, The metabolism of Practolol can be decreased when combined with Dolasetron.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Dolasetron.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Dolasetron is combined with Prazepam.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Prenylamine.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Prilocaine is combined with Dolasetron.]
[P01BA03, primaquine, The metabolism of Dolasetron can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Dolasetron can be increased when combined with Primidone.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Probucol.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Dolasetron.]
[S01HA05, procaine, The risk or severity of adverse effects can be increased when Procaine is combined with Dolasetron.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Procarbazine.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Dolasetron.]
[N04AA04, procyclidine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Dolasetron can be decreased when combined with Progesterone.]
[N05AA03, promazine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Promazine.]
[R06AD02, promethazine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[C01BC03, propafenone, The metabolism of Dolasetron can be decreased when combined with Propafenone.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Dolasetron is combined with Propanidid.]
[A03AB05, propantheline, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Periciazine.]
[N05CM06, propiomazine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Dolasetron is combined with Propofol.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dolasetron.]
[C07AA05, propranolol, The metabolism of Dolasetron can be decreased when combined with Propranolol.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Dolasetron is combined with Rizatriptan.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Dolasetron.]
[R01BA02, pseudoephedrine, The risk or severity of serotonin syndrome can be increased when Dolasetron is combined with Pseudoephedrine.]
[N05AX12, aripiprazole, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.]
[A03AB15, diphemanil, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Dolasetron.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Dolasetron is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Dolasetron is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Dolasetron is combined with Pyrantel.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Dolasetron is combined with Mepyramine.]
[C01BA01, quinidine, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Quinidine.]
[P01BC01, quinine, The metabolism of Dolasetron can be decreased when combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Dolasetron can be decreased when combined with Ranitidine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Dolasetron.]
[J04AB02, rifampin, The metabolism of Dolasetron can be increased when combined with Rifampicin.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Dolasetron is combined with Oxitriptan.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Roxithromycin.]
[S01FA02, scopolamine, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Dolasetron.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Dolasetron is combined with Selegiline.]
[C07AA07, sotalol, The metabolism of Sotalol can be decreased when combined with Dolasetron.]
[R03BB01, ipratropium bromide, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
